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Extrapyramidal Side Effects of Antipsychotic Treatment:
Scope of Problem and Impact on Outcome
Rajiv Tandon, MD1,2 and Michael D. Jibson, MD, PhD1
Previously, clinicians worked with antipsychotic drugs (conventional or typical) that almost
invariably caused extrapyramidal symptoms (EPS) at clinically effective doses. This led to
the false impression that all antipsychotics were the same, and that EPS were an unavoid-
able consequence of effective antipsychotic therapy. EPS adversely impact several aspects
of antipsychotic efficacy and tolerability, thereby worsening outcome of afflicted individuals.
EPS reduce beneficial effects of antipsychotic treatment on the negative, cognitive, and mood
symptom domains, while increasing the risk of tardive dyskinesia and reducing compliance. By
definition, the newer generation of “atypical” antipsychotic agents are significantly better than
conventional agents with regard to EPS (i.e., they are clinically effective at doses at which they
do not cause EPS). Pharmacologically, this difference is expressed in the greater degree of sep-
aration between respective dose response curves for antipsychotic and EPS effects observed
for “atypical” in contrast to conventional agents. Clinically, this EPS advantage of atypical
antipsychotics translates into several important benefits, including better negative symptom
efficacy, less dysphoria, less impaired cognition, a lower risk of TD, and better overall outcome.
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INTRODUCTION
The past decade has witnessed an unprecedented
development of a new generation of so-called “atypi-
cal” antipsychotic medications. Following the intro-
duction of clozapine in the United States in 1990,
risperidone, olanzapine, quetiapine, and ziprasidone
have become available for general clinical practice.
As with their neuroleptic predecessors, these medica-
tions are effective in reducing the delusional thinking,
hallucinatory experiences, and thought disorganiza-
tion that are the hallmarks of psychosis. Compared to
older medications, however, these agents are associ-
ated with a much lower risk of extrapyramidal side
effects (EPS), which were a bane of the older genera-
tion of conventional antipsychotics. In contrast to the
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older conventional antipsychotics, the newer atypical
antipsychotics are better able to separate the thera-
peutic antipsychotic effect from EPS (1–6).
EXTRAPYRAMIDAL SYNDROMES AND
THEIR CLINICAL IMPLICATIONS
Several extrapyramidal syndromes are asso-
ciated with antipsychotic treatment. These in-
clude dystonic reactions, drug-induced parkinsonism,
akathisia, akinesia, and dyskinesia. Each of these syn-
dromes can occur acutely or late (“tardive”) in the
course of antipsychotic treatment and is associated
with a variety of mental and other consequences.
These consequences of the various syndromes are
briefly reviewed.
Dystonia and Drug-Induced Parkinsonism
Acute dystonic reactions are common during
neuroleptic treatment, particularly with initial doses
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of the medication; such reactions are painful and
frightening and patients are predictably resistant to
continuing medication following such an event. Dys-
tonic reactions can also occur later in treatment, and
this too can result in poor patient compliance be-
cause they are one of the most frightening aspects
of antipsychotic therapy. Among patients who con-
tinue to take the medication, parkinsonian side effects
(tremor, bradykinesia, and rigidity) impair social and
occupation function, adding to the likelihood of dete-
rioration in these areas.
Although the motor symptoms of EPS are well
recognized, mental manifestations are not. Mental as-
pects of parkinsonism include emotional withdrawal,
anhedonia, and restricted affect in the emotional do-
main; apathy, social withdrawal, diminished social
drive and initiative in the social realm; and impaired
concentration and sluggish thought processes in the
cognitive domain (7). Mental aspects of EPS, along
with subjective akathisia, are one of the main reasons
for negative attitudes of patients and caregivers to-
ward antipsychotics.
Akathisia and Noncompliance
Akathisia is common, often goes unrecognized
by patients and physicians, and is associated with pre-
mature treatment termination because it is one of
the most distressing side effects associated with an-
tipsychotic treatment. Psychological akathisia is an
uncomfortable feeling of restlessness and uneasiness.
The occurrence of akathisia in the course of antipsy-
chotic treatment has been related to exacerbation of
psychotic symptoms (8) and increased suicidality (9).
Akathisia is associated with extreme subjective dis-
tress, and its occurrence in the course of antipsychotic
treatment results in high rates of noncompliance (10,
11). Medication noncompliance, in turn, is associated
with a threefold increase in the risk of relapse (12, 13).
Akinesia and Negative Symptoms
Bradykinesia/akinesia is a drug-induced ex-
trapyramidal syndrome characterized by reduced fa-
cial expression, decreased spontaneity, apathy, loss of
expressive gestures, and flattening of vocal inflection;
notably, these are also among the negative symptoms
of schizophrenic illness. It should be noted that neg-
ative symptoms in schizophrenic patients may arise
from a variety of causes, some inherent to the illness
(primary symptoms), and some secondary to treat-
Fig. 1. Negative symptoms in schizophrenic patients may arise from
various causes (7). These symptoms can be improved or worsened
by treatment; antipsychotic agents improve the component of neg-
ative symptoms associated with positive symptoms, but the agents
also can worsen negative symptoms associated with EPS.
ment or other psychosocial factors (Fig. 1) (14, 15).
Distinguishing between different causes of negative
symptoms is useful from a pathophysiological and
management standpoint. It should be emphasized,
however, that all components of negative symptoms
have an adverse impact on outcome. Negative symp-
toms associated with EPS are disabling just as deficit
or primary enduring negative symptoms are (14).
Antipsychotics reduce negative symptoms as-
sociated with positive symptoms, while sometimes
adding negative symptoms related to EPS. This contri-
bution of “secondary” negative symptoms may offset
the benefits of these medications in treating negative
symptoms associated with psychotic symptoms (16,
17). Because EPS may partially offset gains in neg-
ative symptoms associated with resolution of active
psychosis, the newer atypical antipsychotics (because
they are less likely to cause EPS) have generally been
found to be more effective than conventional agents
in ameliorating negative symptoms (17–19).
EPS and Cognitive Impairment
In addition to their motor symptoms, neurolep-
tics have been associated with cognitive dysfunction,
attributable directly to EPS, to their inherent an-
ticholinergic properties, and to the adjunctive use
of other anticholinergic agents (20, 21). Cognitive
impairment has long been described as a feature
of schizophrenic illness, independent of positive or
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negative symptoms. Conventional neuroleptics have
only minor effects on most aspects of cognition in
schizophrenia (22, 23). There is some beneficial effect
of typical neuroleptic treatment on measures of atten-
tion and distractibility (15). On the other hand, neu-
roleptic blockade of mesocortical dopamine transmis-
sion adversely impacts several aspects of cognitive
function and results in bradyphrenia, characterized
by slowed mentation and decreased cognitive abil-
ity. Anticholinergic activity (either intrinsic to the an-
tipsychotic agent or due to the addition of an anti-
cholinergic agent to treat parkinsonian side effects)
adversely affects memory, learning, and other cogni-
tive functions (21, 24, 25). Since atypical agents are
less likely than conventional neuroleptics to cause ex-
trapyramidal side effects (EPS) or require the addi-
tion of adjunctive anticholinergic to treat EPS, mod-
est cognitive advantages of these agents could be
expected (26). Recent studies suggest that atypical
antipsychotics do have a greater beneficial effect on
cognitive function in schizophrenic patients (27–29).
EPS and Depression
It is not surprising that significant EPS may be
correlated with dysphoria. Neuroleptic-induced aki-
nesia and depression show a substantial phenomeno-
logical overlap (akinetic depression). In turn, depres-
sive symptoms in psychotic illness have been related
to substance abuse, suicidality, medication noncom-
pliance, and greater morbidity (30–33). Atypical an-
tipsychotics, possibly related to their lower propensity
to cause EPS, have generally been found to be more
efficacious than conventional antipsychotics in ame-
liorating the depressive symptoms in schizophrenia
(18, 19).
EPS and Tardive Dyskinesia
Tardive dyskinesia, a movement disorder char-
acterized by choreoathetoid and stereotyped involun-
tary movements, generally appears after several years
of antipsychotic treatment. Early expression of EPS
significantly increases the likelihood of subsequently
developing tardive dyskinesia (34–36). Tardive dysk-
inesia, in turn, adds to the stigma associated with the
illness, is disfiguring, and may hasten the patient’s
decline in social function; it is also associated with
increased mortality. Atypical antipsychotics are pre-
dicted to be less likely to cause tardive dyskinesia be-
cause of their lower propensity to cause EPS (37, 38).
EPS and Sense of Well-Being
Symptoms of drug-induced parkinsonism are ex-
tremely distressing to patients, even though many
patients do not spontaneously complain about these
symptoms. A majority of patients find the subjective
symptoms of EPS to be more distressing than the out-
wardly obvious physical signs (10). Subjective symp-
toms of EPS include dullness and apathy, “a zombie-
like feeling,” and inner restlessness. It should be noted
that many of these symptoms resemble aspects of
schizophrenic psychopathology and their appearance
can easily lead to the misstep of increasing the dose of
the offending agent, thereby compounding the prob-
lem (10). An antipsychotic with a low incidence of
EPS (atypical vs. conventional antipsychotics) thus
can substantially improve patient comfort and sim-
plify patient management (39, 40).
EPS and Outcome
The occurrence of EPS in the course of antipsy-
chotic treatment is associated with poor response
and reduced efficacy (41). EPS adversely impact the
already-compromised level of function and quality
of life of individuals suffering from schizophrenic
illness. They contribute to stigmatization of the pa-
tient and increase the burden on caregivers. Patients
treated with atypical antipsychotics have generally
been found to exhibit better long-term outcome than
those treated with conventional antipsychotics (13).
WHAT DO THE NEWER “ATYPICAL
ANTIPSYCHOTICS” OFFER?
The defining characteristic of atypical antipsy-
chotics is at least equal efficacy with a significantly
lower liability of EPS than conventional agents; con-
sequently, their use would be predicted to yield sev-
eral benefits that go beyond reduction in parkinso-
nian motor side effects. Many of these advantages
have been confirmed in clinical studies, but the pu-
tative benefits of atypicals on lowering EPS have
different degrees of substantiation in the literature
(Fig. 2). Therefore, to derive optimal benefits from
the use of atypical antipsychotics, it is essential that
they be used in a way that EPS not occur; if EPS occur
in the course of treatment with an atypical antipsy-
chotic, consideration should be given to a reduction
in dose or change to another agent. Adequate control
of psychotic symptoms with avoidance of EPS without
P1: IBC
Annals of Clinical Psychiatry (ACLI) PP557-377854-06 August 9, 2002 13:43 Style file version Nov. 07, 2000
126 Tandon and Jibson
Fig. 2. The strength of the evidence varies for the putative benefits of atypical antipsychotics with respect to EPS.
adjunctive antiparkinsonian medication should be the
objective.
Although the newer generation of antipsychotics
are all associated with a lower liability of EPS when
contrasted to the older generation of conventional
antipsychotics (thereby providing the several bene-
fits listed above to patients), there are clear differ-
Fig. 3. A broader degree of separation is seen for all atypical antipsychotics in comparison to conventional antipsychotics. Among atypical
antipsychotics, the different degrees of separation are likely to be reflected in their relative propensity to cause EPS with increasing doses
(11).
ences between them in this regard. This difference
between different atypical antipsychotics with regard
to the ease and consistency with which they pro-
vide this EPS advantage is reflected in the degree
of separation between their respective antipsychotic
and EPS dose–response curves (Fig. 3) (19, 37, 42).
These different degrees of separation are of particular
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relevance in vulnerable patient populations and as
the dosage of the “atypical” antipsychotic agent is in-
creased. Whereas clozapine and quetiapine are not
associated with any dose-dependent increase in risk
of EPS across their entire dose range (5), olanzap-
ine and ziprasidone can be associated with EPS (par-
ticularly akathisia) at their higher doses (4, 43), and
risperidone is associated with a clear dose-dependent
increase in risk of EPS (3). Regardless, when one uses
any of the newer generation of “atypical” antipsy-
chotics, it is crucial to recognize that the principal fac-
tor contributing to their multiple advantages over the
older conventional agents is their lower liability of
EPS. Consequently, when one uses these agents, it is
essential to obtain a satisfactory antipsychotic effect
without EPS and without using an anticholinergic an-
tiparkinsonian agent; this “essence of atypicality” is
the key to the multiple benefits associated with the
use of the newer generation of antipsychotics.
CONCLUSIONS
The “costs” of EPS are not limited to parkinso-
nian motor manifestations, but extend to increased
negative symptoms and cognitive impairment, more
dysphoria, higher likelihood of noncompliance, and
greater risk of developing tardive dyskinesia (37).
The importance of EPS in the context of treatment
of schizophrenic illness tends to be underestimated.
Fig. 4. The “costs” of EPS extend well beyond parkinsonian motor manifestations.
Expression of EPS significantly increases the
likelihood of subsequent tardive dyskinesia; tar-
dive dyskinesia, in turn, is associated with increased
morbidity and mortality. EPS contribute to sec-
ondary negative symptoms, increasing the severity
of this symptom dimension and attendant dysfunc-
tion. EPS are associated with cognitive dysfunction,
attributable directly to unattenuated mesocortical
dopamine blockade of the antipsychotic or to the ad-
junctive use of other anticholinergic agents to treat
EPS. It is not surprising that significant EPS may be
correlated with dysphoria. The “costs” of EPS are thus
not limited to parkinsonian motor manifestations, but
extend to increased negative and cognitive symptoms,
more dysphoria, higher likelihood of noncompliance,
and greater risk of tardive dyskinesia. These implica-
tions of various EPS are depicted in Fig. 4.
The new atypical antipsychotic medications rep-
resent a major step forward in the treatment of
schizophrenia and other psychotic disorders. These
agents are pharmacologically distinct from their neu-
roleptic predecessors. The primary advantage of the
new agents is their superior side effect profiles, par-
ticularly with regard to EPS. The implications of EPS
reduction touch virtually every domain of pathol-
ogy in schizophrenia, including short- and long-term
movement disorders, negative symptoms, noncompli-
ance, relapse rate, cognitive dysfunction, and dyspho-
ria. This EPS advantage of atypical antipsychotics is
likely to lead to improved patient compliance and a
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superior long-term outcome in patients treated with
these medications.
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